Tatjana Heinrich

Tatjana Heinrich has a wealth of experience in the field of research and drug development. Tatjana began their career in 1994 as a Research Officer at Murdoch University. In 1999, they moved to Industrial Biosystems as a Research Officer. In 2001, they became a Senior Research Officer at the Telethon Institute for Child Health Research. In 2008, they were a Senior Research Scientist at Phylogica Limited. In 2009, they became the Group Leader Discovery & Screening at PYC Therapeutics. In 2020, they were a Rapid Covid Testing at Avicena Systems Pty Ltd, and a Senior Team Leader Rapid Covid Testing at the Perron Institute for Neurological and Translational Science. Most recently, in 2022, they were appointed as the Head of Preclinical Drug Development at Emyria (ASX:EMD).

Tatjana Heinrich began their education in 1974 at Albertus Magnus Schule in Viernheim, Germany. Tatjana then went on to earn a Bachelor's degree and Honours in Biochemistry from Freie Universität Berlin in 1988. Finally, they completed their Doctor of Philosophy - PhD in Biochemistry and Molecular Biology from Freie Universität Berlin in 1993.